The SARAH Study
The SARAH study (SorAfenib versus Radioembolisation in Advanced Hepatocellular carcinoma) is a Phase III, open-label randomised controlled trial in locally advanced or inoperable Hepatocellular Carcinoma (HCC).
SARAH was an investigator study sponsored by Assistance Publique – Hôpitaux de Paris (AP-HP) and supported by Sirtex Medical Limited.
The SARAH study was launched in December 2011 and concluded enrolment in February 2015.
SARAH Study Design
SARAH was designed to directly compare the efficacy and safety of SIR-Spheres® Y-90 resin microspheres with sorafenib, a systemic treatment, currently the standard of care in advanced hepatocellular carcinoma.
With 459 patients treated in 25 clinical centres across France, SARAH is the largest randomised study ever to compare Selective Internal Radiation Therapy (SIRT) - or any liver-directed therapy - against the standard-of-care systemic therapy in the treatment of primary liver cancer.